使用Satelia®Cardio远程监测慢性心力衰竭患者的安全性和性能:来自现实世界使用的第一个结果

J. Patrick, Picard F, Girerd N, Lemieux H, Barritault F, Seronde Mf, Labarre Jp, Pages N, Bedel C, Betito L, Nisse-Durgeat S, Diebold B
{"title":"使用Satelia®Cardio远程监测慢性心力衰竭患者的安全性和性能:来自现实世界使用的第一个结果","authors":"J. Patrick, Picard F, Girerd N, Lemieux H, Barritault F, Seronde Mf, Labarre Jp, Pages N, Bedel C, Betito L, Nisse-Durgeat S, Diebold B","doi":"10.29328/journal.jccm.1001152","DOIUrl":null,"url":null,"abstract":"Background: Since 2019, remote patient monitoring (RPM) for patients with chronic heart failure (CHF) has been supported by the European Society of Cardiology. However, real-world data on the use of such solutions has been limited and not primarily based on patient-reported outcomes. The aim of this study was to describe the Satelia® Cardio solution in France within the French ETAPES funding program and assess the security and performance of its clinical algorithm. Methods: A retrospective observational study was conducted on CHF patients monitored by RPM through Satelia® Cardio. From September 1, 2018, to June 30, 2020, patients were included if they had completed over six months of follow-up. The risk of a possible CHF decompensation was categorized by the system in three levels: green, orange and red. The algorithm security and performance were assessed through the negative predictive value (NPV) of the prediction of hospitalization of a patient within seven days. Results: In total, 331 patients were included in this study with 36,682 patient self-administered questionnaires answered. Patients were mostly males (70.4%) and had a mean age of 68.1 years. The mean left ventricular ejection fraction (LVEF) was 35.4% (± 12.3) and 73.3% of patients had a LVEF ≤ 40%. The questionnaire response rate was 90.9%. A green status was generated for 95.3% of answers. There were 4.5% (n = 1,499) orange alerts and 0.2% (n = 74) red alerts. Overall, 92.1% of patients had at least one CHF related hospitalization and 31.7% (n = 105) of these cases were non-scheduled. The NPV at seven days was 99.43%. Conclusion: Satelia® Cardio is a feasible, relevant and reliable solution to safely monitor the cohorts of patients with CHF, reassuring cardiologists about patient stability.","PeriodicalId":92232,"journal":{"name":"Journal of cardiology and cardiovascular medicine","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Security and performance of remote patient monitoring for chronic heart failure with Satelia® Cardio: First results from real-world use\",\"authors\":\"J. Patrick, Picard F, Girerd N, Lemieux H, Barritault F, Seronde Mf, Labarre Jp, Pages N, Bedel C, Betito L, Nisse-Durgeat S, Diebold B\",\"doi\":\"10.29328/journal.jccm.1001152\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Since 2019, remote patient monitoring (RPM) for patients with chronic heart failure (CHF) has been supported by the European Society of Cardiology. However, real-world data on the use of such solutions has been limited and not primarily based on patient-reported outcomes. The aim of this study was to describe the Satelia® Cardio solution in France within the French ETAPES funding program and assess the security and performance of its clinical algorithm. Methods: A retrospective observational study was conducted on CHF patients monitored by RPM through Satelia® Cardio. From September 1, 2018, to June 30, 2020, patients were included if they had completed over six months of follow-up. The risk of a possible CHF decompensation was categorized by the system in three levels: green, orange and red. The algorithm security and performance were assessed through the negative predictive value (NPV) of the prediction of hospitalization of a patient within seven days. Results: In total, 331 patients were included in this study with 36,682 patient self-administered questionnaires answered. Patients were mostly males (70.4%) and had a mean age of 68.1 years. The mean left ventricular ejection fraction (LVEF) was 35.4% (± 12.3) and 73.3% of patients had a LVEF ≤ 40%. The questionnaire response rate was 90.9%. A green status was generated for 95.3% of answers. There were 4.5% (n = 1,499) orange alerts and 0.2% (n = 74) red alerts. Overall, 92.1% of patients had at least one CHF related hospitalization and 31.7% (n = 105) of these cases were non-scheduled. The NPV at seven days was 99.43%. Conclusion: Satelia® Cardio is a feasible, relevant and reliable solution to safely monitor the cohorts of patients with CHF, reassuring cardiologists about patient stability.\",\"PeriodicalId\":92232,\"journal\":{\"name\":\"Journal of cardiology and cardiovascular medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-05-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of cardiology and cardiovascular medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.29328/journal.jccm.1001152\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cardiology and cardiovascular medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29328/journal.jccm.1001152","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:自2019年以来,慢性心力衰竭(CHF)患者的远程患者监测(RPM)得到了欧洲心脏病学会的支持。然而,关于使用此类解决方案的实际数据有限,而且主要不是基于患者报告的结果。本研究的目的是在法国ETAPES资助项目中描述法国的Satelia®Cardio解决方案,并评估其临床算法的安全性和性能。方法:对通过Satelia®Cardio进行RPM监测的CHF患者进行回顾性观察研究。从2018年9月1日至2020年6月30日,如果患者完成了6个月以上的随访,则纳入患者。瑞士法郎可能失偿的风险被系统分为三个级别:绿色、橙色和红色。通过预测患者7天内住院的负预测值(NPV)来评估算法的安全性和性能。结果:本研究共纳入331例患者,共回复36682份患者自填问卷。患者以男性居多(70.4%),平均年龄68.1岁。平均左室射血分数(LVEF)为35.4%(±12.3),73.3%的患者LVEF≤40%。问卷回复率为90.9%。95.3%的回答为绿色状态。有4.5% (n = 1499)的橙色警报和0.2% (n = 74)的红色警报。总体而言,92.1%的患者至少有一次与CHF相关的住院治疗,其中31.7% (n = 105)的患者未安排住院治疗。7天NPV为99.43%。结论:Satelia®Cardio是一种可行、相关和可靠的解决方案,可安全监测CHF患者队列,使心脏病专家对患者的稳定性放心。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Security and performance of remote patient monitoring for chronic heart failure with Satelia® Cardio: First results from real-world use
Background: Since 2019, remote patient monitoring (RPM) for patients with chronic heart failure (CHF) has been supported by the European Society of Cardiology. However, real-world data on the use of such solutions has been limited and not primarily based on patient-reported outcomes. The aim of this study was to describe the Satelia® Cardio solution in France within the French ETAPES funding program and assess the security and performance of its clinical algorithm. Methods: A retrospective observational study was conducted on CHF patients monitored by RPM through Satelia® Cardio. From September 1, 2018, to June 30, 2020, patients were included if they had completed over six months of follow-up. The risk of a possible CHF decompensation was categorized by the system in three levels: green, orange and red. The algorithm security and performance were assessed through the negative predictive value (NPV) of the prediction of hospitalization of a patient within seven days. Results: In total, 331 patients were included in this study with 36,682 patient self-administered questionnaires answered. Patients were mostly males (70.4%) and had a mean age of 68.1 years. The mean left ventricular ejection fraction (LVEF) was 35.4% (± 12.3) and 73.3% of patients had a LVEF ≤ 40%. The questionnaire response rate was 90.9%. A green status was generated for 95.3% of answers. There were 4.5% (n = 1,499) orange alerts and 0.2% (n = 74) red alerts. Overall, 92.1% of patients had at least one CHF related hospitalization and 31.7% (n = 105) of these cases were non-scheduled. The NPV at seven days was 99.43%. Conclusion: Satelia® Cardio is a feasible, relevant and reliable solution to safely monitor the cohorts of patients with CHF, reassuring cardiologists about patient stability.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信